Houston Attorney Erin Copeland Appointed to Plaintiffs' Steering Committee for Transvaginal Mesh MDL

Share Article

Attorney Erin Copeland of the Fibich Hampton Law Firm in Houston has been appointed to the Plaintiffs' Steering Committee for the transvaginal mesh MDL actions against J&J, American Medical Systems, and Boston Scientific.

Attorney Erin Copeland

On the heels of the initial pre-trial conference in Charleston, WV last week, Judge Joseph R. Goodwin has issued orders identifying Plaintiffs' Steering Committee for the transvaginal mesh MDL actions against manufacturing giants Johnson & Johnson, American Medical Systems, and Boston Scientific. Select attorneys from across the country have been appointed to serve in committee and other leadership roles to coordinate the prosecution of injury claims arising from transvaginal mesh devices manufactured by these entities. Attorney Erin Copeland has been selected to serve as a member of the committee.

The three MDLs are pending in the United States District Court for the Southern District of West Virginia - Charleston Division and styled: MDL No. 2325 | In Re American Medical Systems, Inc., Pelvic Repair System Products Liability Litigation; MDL No. 2326 | In Re Boston Scientific Corp. Pelvic Repair System Products Liability Litigation; and MDL No. 2327 | In Re Ethicon, Inc., Pelvic Repair System Products Liability Litigation.

Attorney Erin Copeland works with Fibich, Hampton, Leebron, Briggs & Josephson – a civil litigation firm based in Houston, Texas. The law firm is known for its work on pharmaceutical cases and other members have served or are currently serving in leadership positions on other consolidated pharmaceutical cases. Transvaginal mesh claims are one of many currently being prosecuted by the firm.

In July 2011, the FDA issued a News Release warning of the dangers associated with synthetic transvaginal mesh - including the types of mesh manufactured by Johnson & Johnson, Boston Scientific, American Medical Systems, Bard, and many others. The FDA safety communication warned that transvaginal placement of mesh may expose women to more danger than other surgical options. It also says that with the exposure to greater risk comes no evidence of greater clinical benefit such as improved quality of life.

The injuries associated with synthetic transvaginal mesh are serious and life altering and can include mesh erosion, severe pain, infection, bleeding, pain with intercourse, and urinary problems.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Erin Copeland

7137510025
Email >
Visit website